APA (7th ed.) Citation

LM, M., C, H., SE, K., P, W., S, B., S, H., . . . E, R. (2025). CAR-CIK vs. CAR-T: Benchmarking novel cytokine-induced killer cells as solid tumor immunotherapy in ErbB2+ rhabdomyosarcoma. Frontiers in immunology, 16, 1485817. https://doi.org/10.3389/fimmu.2025.1485817

Chicago Style (17th ed.) Citation

LM, Moser, et al. "CAR-CIK Vs. CAR-T: Benchmarking Novel Cytokine-induced Killer Cells as Solid Tumor Immunotherapy in ErbB2+ Rhabdomyosarcoma." Frontiers in Immunology 16 (2025): 1485817. https://doi.org/10.3389/fimmu.2025.1485817.

MLA (9th ed.) Citation

LM, Moser, et al. "CAR-CIK Vs. CAR-T: Benchmarking Novel Cytokine-induced Killer Cells as Solid Tumor Immunotherapy in ErbB2+ Rhabdomyosarcoma." Frontiers in Immunology, vol. 16, 2025, p. 1485817, https://doi.org/10.3389/fimmu.2025.1485817.